Free Trial
NYSE:GSK

GSK (GSK) Stock Price, News & Analysis

$45.15
-0.63 (-1.38%)
(As of 03:15 PM ET)
Today's Range
$44.94
$45.77
50-Day Range
$39.28
$45.77
52-Week Range
$33.33
$45.92
Volume
4.13 million shs
Average Volume
3.54 million shs
Market Capitalization
$93.57 billion
P/E Ratio
16.36
Dividend Yield
3.26%
Price Target
N/A

GSK MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.44% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.29mentions of GSK in the last 14 days
Based on 26 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
9.76%
From $4.10 to $4.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.21 out of 5 stars

Medical Sector

537th out of 921 stocks

Pharmaceutical Preparations Industry

249th out of 426 stocks

GSK stock logo

About GSK Stock (NYSE:GSK)

GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical company headquartered in Brentford, London. It operates in three main business areas: pharmaceuticals, vaccines and consumer healthcare products. The company has a global presence, operating in over 150 countries and employing over 94,000 people worldwide.

GSK has a long history of innovation and has been responsible for developing some of the world's most important medicines, including treatments for asthma, HIV/AIDS and cancer. The company is also committed to global health initiatives, focusing on improving access to essential medicines in developing countries.

Emma Walmsley has been the CEO of GSK since 2017, becoming the first female CEO of a major pharmaceutical company. She has been instrumental in transforming the company's operations and has led a significant restructuring effort to simplify the business and focus on key growth areas. The management team includes several other key executives, including Dr. Hal Barron, former President of Research and Development, now a Non-Executive Director and Luke Miels, Chief Commercial Officer.

GSK's financial performance has been mixed in recent years. The company's revenue has been relatively flat over the past few years, and rising R&D costs and the impact of COVID-19 on sales have impacted profitability. In Q2 - Q4 of 2022, the company's stock price dropped nearly 40% concerning long-term shareholders. This stock has underperformed the broader market and many of its peers in the pharmaceutical industry. However, this also points to the fact that the stock is undervalued relative to its peers providing good value for would-be investors.

GSK has also undergone significant changes in ownership in recent years. In 2019, the company merged its consumer healthcare business with Pfizer's consumer healthcare business to create a new joint venture. GSK owns a majority stake in the joint venture, which is expected to generate significant cost savings and synergies.

The pharmaceutical industry is highly competitive, with a few major players dominating the market. GSK's primary competitors include Pfizer, Johnson & Johnson and Roche. The industry is also heavily regulated, with stringent drug safety and efficacy requirements.

One of the key trends in the industry is the shift toward personalized medicine, which involves developing treatments tailored to individual patients based on their genetic makeup. GSK has invested heavily in this area, focusing on oncology and rare diseases.

Despite the pharmaceutical industry's challenges, GSK has several growth opportunities in its core business areas. The company has a strong pipeline of new drugs and vaccines in development, including several potential blockbusters. GSK is also expanding its presence in emerging markets, where demand for healthcare products is growing rapidly.

In addition, the company has been exploring opportunities in digital health and artificial intelligence, which could transform how medicines are developed and delivered. GSK is also committed to sustainability and has set ambitious targets to reduce its environmental impact and improve access to healthcare in low-income countries.

The pharmaceutical industry is subject to a range of risks and challenges, including regulatory hurdles, patent expirations and intense competition. GSK is not immune to these risks and faces some specific challenges.

The COVID-19 pandemic is one of the biggest challenges facing GSK. Another risk is the potential for increased regulatory scrutiny. The pharmaceutical industry is pressured to demonstrate that its products are safe and effective. GSK has faced significant fines and penalties for regulatory violations.

GSK faces competition from established players in the industry and new entrants, particularly in digital health. As a result, the company will need to continue to invest in innovation and R&D to maintain its competitive position and drive growth in the future.

GSK Stock Price History

GSK Stock News Headlines

GSK to divest remaining 4.2% stake in Haleon
GSK Sells Last Haleon Shares for $1.58 Bln
GSK goes ex dividend tomorrow
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 4/11 Dividend
2/22/2024
Dividend Payable
4/11/2024
Last Earnings
5/01/2024
Ex-Dividend for 7/11 Dividend
5/16/2024
Today
5/23/2024
Dividend Payable
7/11/2024
Next Earnings (Estimated)
7/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
70,200
Year Founded
2000

Profitability

Net Income
$6.13 billion
Pretax Margin
17.97%

Debt

Sales & Book Value

Annual Sales
$37.71 billion
Cash Flow
$5.26 per share
Book Value
$8.09 per share

Miscellaneous

Outstanding Shares
2,072,440,000
Free Float
1,865,196,000
Market Cap
$93.53 billion
Optionable
Optionable
Beta
0.65

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Ms. Emma Natasha Walmsley (Age 55)
    CEO & Director
    Comp: $6.85M
  • Ms. Julie Belita Brown (Age 62)
    CFO & Executive Director
    Comp: $6.54M
  • Ms. Shobie Ramakrishnan (Age 53)
    Chief Digital & Technology Officer
  • Mr. Tony Wood
    Chief Scientific Officer and Head of R&D
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Senior VP & Group General Counsel of Legal & Compliance
  • Ms. Sally JacksonMs. Sally Jackson
    Senior Vice President of Global Communications & CEO Office
  • Mr. David Simon Redfern BSc (Hons) (Age 58)
    CA, President of Corporate Development
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. Philip C. Thomson
    President of Global Affairs

GSK Stock Analysis - Frequently Asked Questions

Should I buy or sell GSK stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

How have GSK shares performed in 2024?

GSK's stock was trading at $37.06 on January 1st, 2024. Since then, GSK shares have increased by 21.8% and is now trading at $45.13.
View the best growth stocks for 2024 here
.

Are investors shorting GSK?

GSK saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 8,990,000 shares, an increase of 22.3% from the April 15th total of 7,350,000 shares. Based on an average trading volume of 3,370,000 shares, the short-interest ratio is presently 2.7 days. Currently, 0.4% of the shares of the stock are sold short.
View GSK's Short Interest
.

When is GSK's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024.
View our GSK earnings forecast
.

How were GSK's earnings last quarter?

GSK plc (NYSE:GSK) released its quarterly earnings data on Wednesday, May, 1st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts' consensus estimates of $0.94 by $0.15. The pharmaceutical company had revenue of $9.34 billion for the quarter, compared to analysts' expectations of $8.98 billion. GSK had a trailing twelve-month return on equity of 51.54% and a net margin of 14.62%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK announced a quarterly dividend on Wednesday, May 1st. Shareholders of record on Friday, May 17th will be paid a dividend of $0.3762 per share on Thursday, July 11th. This represents a $1.50 annualized dividend and a yield of 3.33%. The ex-dividend date is Thursday, May 16th. This is a boost from the stock's previous quarterly dividend of $0.36.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (NYSE:GSK) pays an annual dividend of $1.47 per share and currently has a dividend yield of 3.32%. The dividend payout ratio is 53.26%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 32.67% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

What guidance has GSK issued on next quarter's earnings?

GSK updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of 2.120-2.160 for the period, compared to the consensus estimate of 3.960. The company issued revenue guidance of $41.2 billion-$41.2 billion, compared to the consensus revenue estimate of $39.6 billion.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

Who are GSK's major shareholders?

GSK's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include JTC Employer Solutions Trustee Ltd (1.02%), Price T Rowe Associates Inc. MD (0.55%), Mondrian Investment Partners LTD (0.27%), Equity Investment Corp (0.16%), Douglas Lane & Associates LLC (0.11%) and Acadian Asset Management LLC (0.11%).
View institutional ownership trends
.

How do I buy shares of GSK?

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:GSK) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners